Latigo Biotherapeutics Raises $150M in Series B Funding for Non-Opioid Pain Treatments

Latigo Biotherapeutics secures $150 million in Series B financing to advance its non-opioid pain treatments, led by Blue Owl Capital.

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here